US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm Atavistik Bio, with the aim of bolstering the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.
Leverage of Atavistik Bio’s AMPS Platform
Under the agreement, Atavistik Bio will utilize its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer. This strategic collaboration is expected to accelerate the discovery process and potentially lead to breakthrough treatments for conditions with limited therapeutic options.
Option to License Programs Post-Research Completion
Upon the completion of the research, Pfizer will have the option to license the programs developed under this collaboration. This arrangement allows Pfizer to potentially expand its pipeline with innovative allosteric therapeutics, further solidifying its position at the forefront of pharmaceutical research and development.-Fineline Info & Tech
